BiotechTube

AT-527 + Daclatasvir

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatitis C

Conditions

Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection, HCV Infection

Trial Timeline

Jun 20, 2019 → Mar 23, 2020

NCT ID
NCT04019717

About AT-527 + Daclatasvir

AT-527 + Daclatasvir is a phase 2 stage product being developed by Atea Pharmaceuticals for Hepatitis C. The current trial status is completed. This product is registered under clinical trial identifier NCT04019717. Target conditions include Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04019717Phase 2Completed

Competing Products

20 competing products in Hepatitis C

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
IVA337 + IVA337 + PlaceboInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
85
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
77
SOF + COPEChugai PharmaceuticalPre-clinical
23
Colesevelam HclDaiichi SankyoPhase 2
52
ASP9831 + PlaceboAstellas PharmaPhase 2
52
FK788Astellas PharmaPhase 2
52
MK-2248MerckPhase 1
33
Interferon alfacon-1Astellas PharmaPhase 3
77
Pegylated Interferon + RibavirinAstellas PharmaApproved
85
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir + MethadoneShionogiPhase 1
33
Clevudine + AdefovirEisaiPhase 3
77

Other Products from Atea Pharmaceuticals

Bemnifosbuvir (BEM) + PlaceboPhase 3
69
Bemnifosbuvir-Ruzasvir (BEM/RZR) + Sofosbuvir-Velpatasvir (SOF/VEL)Phase 3
69
Bemnifosbuvir-Ruzasvir + Sofosbuvir-VelpatasvirPhase 3
69
Bemnifosbuvir + RuzasvirPhase 2
44
AT-752 + PlaceboPhase 2
44